Vivus Inc (VVUS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
52
About the Report
About the Report
Summary
Vivus Inc (Vivus) is a biopharmaceutical company which develops and commercializes next-generation therapeutics for addressing unmet needs in obesity, sleep apnea, diabetes and sexual health. The company's marketed products include, Qsymia (phentermine and topiramate extended-release), indicated for the chronic weight management in adult patients; and Stendra/Spedra (avanafil), an oral phosphodiesterase type 5, for erectile dysfunction. Its pipeline products include Qsymia for obstructive sleep apnea, nonalcoholic steatohepatitis, diabetes, nonalcoholic fatty liver disease and hyperlipidemia; and Tacrolimus for pulmonary arterial hypertension. Vivus works in partnership with pharmaceutical companies to advance of its product portfolio. It operates through its subsidiaries in the UK, the Netherlands, Ireland and Bermuda. Vivus is headquartered in Campbell, California, the US.
Vivus Inc (VVUS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Vivus Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Vivus Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Vivus Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Vivus Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
VIVUS Acquires Assets from Janssen Pharma for USD135 Million 11
Vivus Acquires Topiramate Related Patents from Janssen Pharma 12
Venture Financing 13
Athyrium Opportunities Invests in Vivus 13
Partnerships 14
Vivus Plans To Enter Into Co-Marketing Agreement For Qsymia 14
Licensing Agreements 15
VIVUS Enters into Licensing Agreement with Selten Pharma 15
Hetero Enters into Licensing Agreement with VIVUS for STENDRA 16
Metuchen Pharma Enters into Licensing Agreement with Vivus 17
Vivus Enters Into Licensing Agreement With Menarini For Spedra 18
Equity Offering 20
Vivus Plans to Raise up to USD200 Million in Public Offering of Securities 20
VIVUS Completes Public Offering Of Common Stock For USD 202 Million 21
Debt Offering 23
Vivus to Raise Funds through public offering of 4.5% Convertible Bonds Due 2020 23
Vivus Completes Private Placement of Notes Due 2020 For USD 220 Million 24
Acquisition 25
Aspen Investment Plans to Acquire Remaining Interest in Vivus for USD640 Million 25
Vivus Inc-Key Competitors 26
Vivus Inc-Key Employees 27
Vivus Inc-Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Financial Announcements 29
Nov 01, 2018: VIVUS reports third quarter 2018 financial results 29
Aug 07, 2018: VIVUS reports second quarter 2018 financial results 31
May 08, 2018: VIVUS Reports First Quarter 2018 Financial Results 33
Mar 13, 2018: VIVUS Reports Fourth Quarter 2017 Financial Results 35
Nov 07, 2017: VIVUS Reports Third Quarter 2017 Financial Results 37
Aug 03, 2017: VIVUS Reports Second Quarter 2017 Financial Results 39
May 03, 2017: VIVUS Reports 2017 First Quarter Financial Results 41
Mar 08, 2017: VIVUS Reports Fourth Quarter and Full Year 2016 Financial Results 42
Corporate Communications 44
Oct 29, 2018: VIVUS adds two new members to the Board of Directors 44
Sep 21, 2018: VIVUS Supports the Cystic Fibrosis Community Through Sponsorship of and Participation in the Cystic Fibrosis Foundation's CF Climb 45
Aug 06, 2018: VIVUS names Kenneth Suh as president 47
Dec 26, 2017: VIVUS Announces Change in Leadership 48
May 24, 2017: Thomas B. King Joins VIVUS' Board of Directors 49
Product Approvals 50
Nov 02, 2017: VIVUS Completes Tacrolimus Pre-IND Meeting With FDA 50
Clinical Trials 51
Jul 10, 2018: VIVUS Announces Positive Results from a Phase 1 Clinical Trial of VI-0106 51
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52
List of Figure
List of Figures
Vivus Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Vivus Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List of Table
List of Tables
Vivus Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Vivus Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Vivus Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Vivus Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
VIVUS Acquires Assets from Janssen Pharma for USD135 Million 11
Vivus Acquires Topiramate Related Patents from Janssen Pharma 12
Athyrium Opportunities Invests in Vivus 13
Vivus Plans To Enter Into Co-Marketing Agreement For Qsymia 14
VIVUS Enters into Licensing Agreement with Selten Pharma 15
Hetero Enters into Licensing Agreement with VIVUS for STENDRA 16
Metuchen Pharma Enters into Licensing Agreement with Vivus 17
Vivus Enters Into Licensing Agreement With Menarini For Spedra 18
Vivus Plans to Raise up to USD200 Million in Public Offering of Securities 20
VIVUS Completes Public Offering Of Common Stock For USD 202 Million 21
Vivus to Raise Funds through public offering of 4.5% Convertible Bonds Due 2020 23
Vivus Completes Private Placement of Notes Due 2020 For USD 220 Million 24
Aspen Investment Plans to Acquire Remaining Interest in Vivus for USD640 Million 25
Vivus Inc, Key Competitors 26
Vivus Inc, Key Employees 27
Vivus Inc, Subsidiaries 28
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.